Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.

Sundling C, Forsell MN, O'Dell S, Feng Y, Chakrabarti B, Rao SS, Loré K, Mascola JR, Wyatt RT, Douagi I, Karlsson Hedestam GB.

J Exp Med. 2010 Aug 30;207(9):2003-17. doi: 10.1084/jem.20100025. Epub 2010 Aug 2. Erratum in: J Exp Med. 2010 Sep 27;207(10):2283.

2.

HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.

Wang Y, O'Dell S, Turner HL, Chiang CI, Lei L, Guenaga J, Wilson R, Martinez-Murillo P, Doria-Rose N, Ward AB, Mascola JR, Wyatt RT, Karlsson Hedestam GB, Li Y.

J Virol. 2017 Oct 13;91(21). pii: e00910-17. doi: 10.1128/JVI.00910-17. Print 2017 Nov 1.

PMID:
28835491
3.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

4.

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation.

Martinez P, Sundling C, O'Dell S, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Rep. 2015 Mar 12;5:8925. doi: 10.1038/srep08925.

6.

Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

McGuire AT, Glenn JA, Lippy A, Stamatatos L.

J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18. Erratum in: J Virol. 2015 May;89(9):5194.

7.

A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.

Ferrantelli F, Maggiorella MT, Schiavoni I, Sernicola L, Olivieri E, Farcomeni S, Pavone-Cossut MR, Moretti S, Belli R, Collacchi B, Srivastava IK, Titti F, Cafaro A, Barnett SW, Ensoli B.

Vaccine. 2011 Apr 5;29(16):2918-32. doi: 10.1016/j.vaccine.2011.02.006. Epub 2011 Feb 21.

PMID:
21338681
8.

Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model.

Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A; NGIN Consortium.

PLoS One. 2013 Sep 2;8(9):e74552. doi: 10.1371/journal.pone.0074552. eCollection 2013.

9.

Human immunodeficiency virus type 1 env trimer immunization of macaques and impact of priming with viral vector or stabilized core protein.

Mörner A, Douagi I, Forsell MN, Sundling C, Dosenovic P, O'Dell S, Dey B, Kwong PD, Voss G, Thorstensson R, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2009 Jan;83(2):540-51. doi: 10.1128/JVI.01102-08. Epub 2008 Nov 12.

10.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

11.

Influence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primates.

Douagi I, Forsell MN, Sundling C, O'Dell S, Feng Y, Dosenovic P, Li Y, Seder R, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

J Virol. 2010 Feb;84(4):1683-95. doi: 10.1128/JVI.01896-09. Epub 2009 Dec 2.

12.

HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.

Bower JF, Li Y, Wyatt R, Ross TM.

Vaccine. 2006 Jun 29;24(26):5442-51. Epub 2006 Apr 3.

PMID:
16621193
13.

Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization.

Dosenovic P, Chakrabarti B, Soldemo M, Douagi I, Forsell MN, Li Y, Phogat A, Paulie S, Hoxie J, Wyatt RT, Karlsson Hedestam GB.

J Immunol. 2009 Sep 1;183(5):3373-82. doi: 10.4049/jimmunol.0900407.

14.

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr, Lifson J, McClure H, Narayan O.

Virology. 2002 Sep 30;301(2):189-205.

15.

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.

Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, Cristillo AD, Ferrai MG, Weiss DE, Letvin NL, Montefiori D, Pal R, Vajdy M.

AIDS. 2008 Jan 30;22(3):339-48. doi: 10.1097/QAD.0b013e3282f3ca57.

PMID:
18195560
16.

High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.

Sundling C, Li Y, Huynh N, Poulsen C, Wilson R, O'Dell S, Feng Y, Mascola JR, Wyatt RT, Karlsson Hedestam GB.

Sci Transl Med. 2012 Jul 11;4(142):142ra96. doi: 10.1126/scitranslmed.3003752.

17.

Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease.

Fultz PN, Stallworth J, Porter D, Novak M, Anderson MJ, Morrow CD.

Virology. 2003 Oct 25;315(2):425-37.

19.

Rhesus macaques vaccinated with consensus envelopes elicit partially protective immune responses against SHIV SF162p4 challenge.

Eugene HS, Pierce-Paul BR, Cragio JK, Ross TM.

Virol J. 2013 Apr 2;10:102. doi: 10.1186/1743-422X-10-102.

20.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

Supplemental Content

Support Center